HMPC meeting report on European Union herbal monographs, guidelines and other activities - 4-6 May 2026

Human medicines European public assessment report (EPAR): Dazparda, insulin aspart, Date of authorisation: 27/04/2026, Status: Authorised

Webinar on new approach methodologies (NAMs) in ecotoxicology: In silico approaches for fish acute toxicity, Online, European Medicines Agency, Amsterdam, the Netherlands, from 28 May 2026, 14:00 (CEST) to 28 May 2026, 15:30 (CEST)

EU tracks progress towards 2030 clinical trial targets

Clinical trials in human medicines

Human medicines European public assessment report (EPAR): Arava, leflunomide, Date of authorisation: 02/09/1999, Revision: 45, Status: Authorised

Human medicines European public assessment report (EPAR): Synflorix, pneumococcal polysaccharide conjugate vaccine (adsorbed), Date of authorisation: 29/03/2009, Revision: 37, Status: Authorised

Human medicines European public assessment report (EPAR): Tecartus, brexucabtagene autoleucel, Date of authorisation: 14/12/2020, Revision: 18, Status: Authorised

Product-specific bioequivalence guidance

Start of procedure: Type II Variation - Extension of indication under evaluation by the CHMP (27 March 2026 - 23 April 2026)